opdivo 10 mg/ml
bristol-myers squibb s.r.l. - italia - nivolumabum - conc. pt. sol. perf. - 10mg/ml - anticorpi monoclonali si conjugati anticorp medicament
orencia 125 mg
bristol-myers squibb s.r.l. - italia - abataceptum - sol. inj. in stilou injector (pen) preumplut - 125mg - imunosupresoare imunosupresoare selective
orencia 125 mg/ml
bristol-myers squibb s.r.l. - italia - abataceptum - sol. inj. in seringa preumpluta - 125mg/ml - imunosupresoare imunosupresoare selective
orencia 250 mg
bristol-myers squibb s.r.l. - italia - abataceptum - pulb. pt. conc. pt. sol. perf. - 250mg - imunosupresoare imunosupresoare selective
sprycel 100 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 100mg - inhibitori de protein-kinaza
sprycel 20 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 20mg - inhibitori de protein-kinaza
sprycel 50 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 50mg - inhibitori de protein-kinaza
sprycel 70 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 70mg - inhibitori de protein-kinaza
yervoy 5 mg/ml
bristol-myers squibb srl - italia - ipilimumabum - conc. pt. sol. perf. - 5mg/ml - anticorpi monoclonali si conjugati anticorp medicament alti anticorpi monoclonali si conjugati anticorp medicament
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanomul - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.